TI
PDSB icon

tru Independence’s PDS Biotechnology PDSB Stock Holding History

tru Independence’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$1 – 697
2020
Q2 		$1 Hold
500
– – ﹤0.01% 858
2020
Q1 		$0 Hold
500
– – ﹤0.01% 857
2019
Q4 		$0 Buy
+500
New +$1.43K ﹤0.01% 939

Other funds holding PDSB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

tru Independence's PDSB Position: Q3 2020 in Review

tru Independence sold out of PDS Biotechnology (PDSB) in Q3 2020, closing a stake of 500 shares — an estimated $1 sold.

tru Independence first reported a position in PDSB in Q4 2019 and held it in 3 quarters. The position peaked at $1 in Q2 2020. 31 funds tracked by Wall St. Rank hold PDSB as of Q3 2020.

  • tru Independence reported no remaining PDS Biotechnology position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 500 PDS Biotechnology shares in Q3 2020, an estimated $1.
  • tru Independence first reported a position in PDS Biotechnology in Q4 2019 and held it in 3 quarters.
  • tru Independence's PDS Biotechnology position peaked at $1 in Q2 2020.
  • 31 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.